Neeraj Saini, MD

Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine

Present Title & Affiliation

Primary Appointment

Associate Professor, Stem Cell Transplantation and Cellular Therapy, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas

Assistant Professor, Lymphoma and Myeloma, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Assistant Professor, Stem Cell Transplantation and Cellular Therapy, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2007	B. J. Medical College, Ahmedabad, Gujarat, IN, Medicine, MD

Postgraduate Training

2018-2019	Clinical Fellowship, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
2017-2018	Chief Fellow, Hematology-Oncology, The University of Massachusetts Medical School, Worcester, Massachusetts
2015-2017	Clinical Fellowship, Hematology-Oncology, The University of Massachusetts Medical School, Worcester, Massachusetts
2010-2013	Clinical Residency, Internal Medicine, North Shore Medical Center, Salem, Massachusetts

Licenses & Certifications

2023	BLS
2019	Controlled Substance Registration Certificate, DEA
2018	American Board of Internal Medicine - Medical Oncology
2018	American Board of Internal Medicine - Hematology
2018	Texas Medical Board
2017	ACLS
2015	Massachusetts Medical License
2013	American Board of Internal Medicine - Internal Medicine
2013	Pennsylvania Medical License

Experience & Service

Faculty Academic Appointments

Clinical Instructor, BMT Division, Thomas Jefferson University Hospital, Philadelphia, PA, 2013 - 2015

Extramural Institutional Committee Activities

Member, IRG Grant Reviewer, The University of Texas MD Anderson Cancer Center, 2022 - Present

Member, CARTOX Database Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present

Member, Scientific Research Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2022

Professional Memberships

American Society of Bone Marrow Transplantation

2017

American Society of Clinical Oncology

2015

American Society of Hematology

2015

American College of Physicians

2010

Grant & Contract Support

Date:	2024 - 2027
Title:	Translation of gut commensal bacteria peptidoglycan remodeling pathway for chimeric antigen receptor T-cell therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI

Date:	2024 - 2027
Title:	Enhancing CAR-T therapeutic responses through innate NOD2 stimulation via microbiome manipulation
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	CA230988

Date:	2024 - 2027
Title:	Enhancing CAR-T therapeutic responses through innate NOD2 stimulation via microbiome manipulation
Funding Source:	Department of Defense (DOD)
Role:	PI
ID:	CA230988

Date:	2024 - 2029
Title:	Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	PAR-22-061

Date:	2023 - 2024
Title:	Functionally validating the role of the microbiome in clinical responses to CD19-targeted CAR-T-cell therapy in large B-Cell lymphoma patients
Funding Source:	MDACC Moonshot Lymphoma
Role:	PI

Date:	2023 - 2024
Title:	Development of Human Nanobody Multimeric CARs against Multiple Myeloma
Funding Source:	MDACC moonshot Myeloma
Role:	Co-PI

Date:	2023 - 2026
Title:	Polyamine inhibitors in CAR-T therapy in lymphoma patients
Funding Source:	Panbela Inc
Role:	PI

Date:	2023 - 2028
Title:	Gut Microbiome Modulation to Reverse Antimicrobial Associated Dysbiosis in CAR T Cell Therapy
Funding Source:	NIH/NCI
Role:	PI

Date:	2022 - 2025
Title:	An International, Multicenter Study to Investigate and Validate Microbiome Configurations and Effectors in CD19-Targeted CAR T Cell Efficacy and Toxicity
Funding Source:	The Mark Foundation
Role:	Co-I

Date:	2021 - 2022
Title:	An international, multicenter study to investigate and validate microbiome and metabolomics to identify novel targetable biomarkers in CD19-targeted CAR-T cell therapy
Funding Source:	IRG/UTMDACC
Role:	PI

Date:	2019 - 2020
Title:	Anti-CD30 Chimeric Antigen Receptor T-Cell Therapy in CD30 Expressing Hematological Malignancies
Funding Source:	IRG/UTMDACC
Role:	PI
ID:	RCTS# 2020-00057976

Selected Publications

Peer-Reviewed Articles

Pasvolsky O, Marcoux C, Milton DR, Haider AA, Tanner MR, Bashir Q, Srour S, Saini N, Smallbone P, Lin P, Ramdial J, Nieto Y, Mohamedi AH, Siddiqui UR, Jamil A, Tang G, Aljawai Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma. Bone Marrow Transplant 61(3):294-302, 2026. e-Pub 2026. PMID: 41350936.
Smallbone P, Mendt M, Sackstein R, Tanner MR, Kaur I, Basar R, Rafei H, Daher M, Overman B, Al-Atrash G, Alousi AM, Bashir Q, Hosing CM, Im JS, Kebriaei P, Banerjee P, Patel KP, Zou J, Cao K, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat UR, Qazilbash MH, Rondon G, Saini N, Srour S, Champlin RE, Rezvani K, Shpall EJ, Olson A. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3):102010, 2026. e-Pub 2026. PMID: 41396090.
Haider AA, Marcoux C, Milton DR, Tanner MR, Bashir Q, Smallbone P, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Siddiqui UR, Aljawai Y, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Lenalidomide maintenance after delayed or salvage autologous stem cell transplantation. Leuk Lymphoma:1-9, 2026. e-Pub 2026. PMID: 41608977.
Joshi V, Vaghela V, Patel N, Saini N, Giri P. Highly Sensitive and Selective Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study. Biomed Chromatogr 40(1):e70288, 2026. e-Pub 2026. PMID: 41378912.
Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Saeed A, Haider AA, Ramdial J, Irfan S, YagoNieto, Tang G, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O. Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis. Transplant Cell Ther, 2025. e-Pub 2025. PMID: 41421540.
Strati P, Brandt A, Lionel AC, Henderson J, Westin JR, Adkins S, Shpall EJ, Kebriaei P, Ramdial J, Saini N, Ahmed S, Flowers C, Neelapu SS, Hildebrandt MAT. Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy. J Immunother Cancer 13(10), 2025. e-Pub 2025. PMID: 41067879.
Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
Pasvolsky O, Marcoux C, Milton DR, Rafaeli N, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Deen AF, Aljawai Y, Lee HC, Patel KK, Becnel MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin R, Shpall EJ, Qazilbash MH. Outcomes of multiple myeloma patients with prior solid tumors undergoing autologous transplantation. Transplant Cell Ther 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
Jhaveri K, Thapa R, Ercan D, Saha A, Noble J, Singh P, Fahrmann J, Saini N, Wu R, Dennison JB, Hanash S, Jenq RR, Modi K, Figura N, Chavez J, Shah B, Nishihori T, Lazaryan A, Khimani F, Bachmeier C, Gage K, Mishra A, Perna F, Davila ML, Spiegel J, Rejeski K, Subklewe M, Locke FL, Freeman C, Parker N, Jain MD. Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell Lymphoma. Clin Cancer Res 31(13):2756-2766, 2025. e-Pub 2025. PMID: 40238583.
Saha S, Rehman L, Rehman A, Darbaniyan F, Weber DM, Becnel M, Gaballa MR, Thomas SK, Lee HC, Chang CC, Arora R, Menges M, Corallo S, Davila ML, Locke FL, Tanner MR, Neelapu SS, Shpall EJ, Flowers CR, Orlowski RZ, Jenq RR, Jain MD, Peterson C, Hansen DK, Saini NY, Patel KK. Longitudinal analysis of gut microbiome and metabolome correlates of response and toxicity with idecabtagene vicleucel. Blood Adv 9(14):3429-3440, 2025. e-Pub 2025. PMID: 40198765.
Manzar, G, Dudzinski, SO, Yoder, A, Seo, A, Nasr, L, Rafei, H, Becnel, M, Patel, K, Lee, HC, Kaufman, GP, Gaballa, MM, Ye, JC, Saini, N, Thomas, SK, Amini, B, Orlowski, R, Dabaja, BS, Pinnix, CC, Gunther, J, Wu, SY, Fang, PQ. Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy. Clinical Lymphoma, Myeloma and Leukemia 25(4):271-284, 2025. e-Pub 2025. PMID: 39709251.
Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
Prasad, R, Rehman, A, Rehman, L, Darbaniyan, F, Blumenberg, V, Schubert, ML, Mor, U, Zamir, E, Schmidt, S, Hayase, T, Chang, C, McDaniel, L, Flores, I, Strati, P, Nair, R, Chihara, D, Fayad, LE, Ahmed, S, Iyer, SP, Wang, ML, Jain, P, Nastoupil, L, Westin, JR, Arora, R, Turner, J, Khawaja, F, Wu, R, Dennison, JB, Menges, M, Hidalgo-Vargas, M, Reid, K, Davila, ML, Dreger, P, Korell, F, Schmitt, A, Tanner, MR, Champlin, RE, Flowers, CR, Shpall, EJ, Hanash, S, Neelapu, SS, Schmitt, M, Subklewe, M, Fahrmann, JF, Thoeringer, C, Elinav, E, Jain, MD, Hayase, E, Jenq, RR, Saini, N. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2025. e-Pub 2025. PMID: 39441941.
Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
Pasvolsky, O, Wang, Z, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Kebriaei, P, Aljawai, YM, Khan, HN, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
Pasvolsky, O, Marcoux, C, Dai, J, Milton, D, Tanner, MR, Syed, N, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Lee, HC, Gaballa, MM, Patel, K, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplantation and Cellular Therapy 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
Fang P, Pinnix CC, Wu SY, Lee HC, Patel KK, Saini N, Becnel MR, Kaufman G, Thomas SK, Orlowski RZ, Amini B, Lin P, Dabaja BS, Gunther JR. Management and Outcomes of Patients with Refractory Solitary Plasmacytoma after Treatment with Definitive Radiation Therapy. Int J Radiat Oncol Biol Phys 119(1):193-199, 2024. e-Pub 2024. PMID: 38070713.
Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2024. PMID: 38127583.
Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol 204(5):1994-1952, 2024. e-Pub 2024. PMID: 38448009.
Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma. Blood Cancer Discov 5(2):106-113, 2024. e-Pub 2024. PMID: 38194367.
Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplant in Patients with Ultra High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem-Cell Transplant For Relapsed or Refractory Primary Mediastinal B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin DC, Nieto Y, Oran B, Saini NY, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil LJ, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler NH, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green MR. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
Singh C, Yanamandra U, Karunakaran P, Jindal N, Kumar SR, Saini N, Jandial A, Jain A, Das C, Lad D, Prakash G, Khadwal A, Naseem S, Das R, Varma N, Varma S, Malhotra P. Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study. Br J Haematol 201(2):249-255, 2023. e-Pub 2023. PMID: 36529704.
Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14). Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
Singh C, Wadhera S, Yanamandra U, Karunakaran P, Jindal N, Kumar SR, Saini N, Jandial A, Jain A, Das C, Prakash G, Khadwal A, Naseem S, Das R, Varma N, Varma S, Malhotra P, Lad D. High-dose hydroxyurea with differentiating agents for treating ultra-high-risk acute promyelocytic leukemia in resource-challenged settings. Acta Oncol 61(12):1512-1514, 2022. e-Pub 2022. PMID: 36579788.
Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. e-Pub 2022. PMID: 36384092.
Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
Saengboon S, Ramdial J, Saini N, Olson A, Im J, Hosing C, Popat U, Shpall E, Champlin R, Srour S. AML-528 Long-Term Outcomes After Haploidentical Stem Cell Transplantation (Haplo-SCT) for Hematologic Malignancies. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S259-S260, 2022. e-Pub 2022. PMID: 36163857.
Pasvolsky O, Milton D, Rauf M, Ghanem S, Masood A, Mohamedi A, Tanner M, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lee H, Patel K, Kebriaei P, Thomas S, Weber D, Orlowski R, Shpall E, Champlin R, Lin P, Qazilbash M. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
Saini N, Neelapu SS. CAR Treg cells: prime suspects in therapeutic resistance. Nat Med 28(9):1755-1756, 2022. e-Pub 2022. PMID: 36109644.
Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical vs Matched Unrelated vs Matched Sibling Donor HCT with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VCD vs. VRD on the Outcome of Patients with Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
Singh S, Roszik J, Saini N, Singh VK, Bavisi K, Wang Z, Vien LT, Yang Z, Kundu S, Davis RE, Bover L, Diab A, Neelapu SS, Overwijk WW, Rai K, Singh M. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade. Front Immunol 13:794684, 2022. e-Pub 2022. PMID: 35720386.
Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
Qazilbash MH, Saini NY, Soung-Chul C, Wang Z, Stadtmauer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, Kim K, Popescu M, Szymura SJ, Zhang T, Anderson AJ, Bashir Q, Shpall EJ, Orlowski RZ, Levine BL, Kerr N, Garfall A, Cohen AD, Vogl DT, Dengel K, June CH, Champlin RE, Kwak LW. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood 139(9):1289-1301, 2022. e-Pub 2022. PMID: 34521108.
Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):710-721, 2022. e-Pub 2022. PMID: 34686083.
Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Graft for Haploidentical HCT with Post Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96(12):E455-E457, 2021. e-Pub 2021. PMID: 34559916.
Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106(12):3211-3214, 2021. e-Pub 2021. PMID: 34407606.
Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. 9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
Saini NY, Bashir Q, Milton DR, Delgado R, Rondon, G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri I, Weber DM, Thomas SK, Lee HC, Patel KP, Orlowski RZ, Champlin R, Qazilbash MH. Busulfan and melphalan conditioning versus melphalan alone in high-risk multiple myeloma. Blood Advances, 2020. e-Pub 2020.
Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv 4(1):47-54, 2020. e-Pub 2020. PMID: 31899797.
Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
Chen J, Pan J, Zhan T, Tuazon S, Saini N, O'Hara W, Filicko-O'Hara J, Klumpp T, Kasner M, Carabasi M, Porcu P, Wagner JL. Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. Biol Blood Marrow Transplant 25(9):e293-e297, 2019. e-Pub 2019. PMID: 31173899.
Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv 3(11):1661-1669, 2019. e-Pub 2019. PMID: 31167818.
Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
Saini NY, Cerny J, Furtado VF, Desmond A, Zhou Z, Raffel G, Puthawala I, Bednarik J, Shanahan L, Miron PM, Woda B, Ramanathan M, Nath R. Elderly do benefit from induction chemotherapy: High dose mitoxantrone-based ("5 + 1") induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. Am J Hematol 94(2):209-215, 2019. e-Pub 2019. PMID: 30417942.
Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
Furtado VF, Saini NY, Walsh W, Bathini V, Miron PM. Rare gene fusion rearrangement SPTNB1-PDGFRB in an atypical myeloproliferative neoplasm. Mol Cytogenet 11:56, 2018. e-Pub 2018. PMID: 30377450.
Saini N, Nath R, Cerny J. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination. Ann Hematol 96(9):1563-1568, 2017. e-Pub 2017. PMID: 28710649.
Kumar V, Balcom J, Patel N, Saini N. Giant Abdominal Aortic Aneurysm. Vascular Diesease Management 10(6):E114-E115, 2013. e-Pub 2013.
Kumar V, Patel N, Van Houzen N, Saini N. Brugada-type electrocardiographic changes induced by fever. Circulation 127(21):2145-6, 2013. e-Pub 2013. PMID: 23716383.
Saini N, Hochberg EP, Linden EA, Jha S, Grohs HK, Sohani AR. HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the Literature. Case Rep Oncol Med 2013:292301, 2013. e-Pub 2013. PMID: 23401819.
Saini N, Pyo Lee K, Jha S, Patel S, Bonthu N, Kansagra A, Bhatia A, Martinez SE, Patel J, Altamimi S, Ghotb S. Hyperuricemic renal failure in nonhematologic solid tumors: a case report and review of the literature. Case Rep Med 2012:314056, 2012. e-Pub 2012. PMID: 22693518.
Agrawal AK, Saini N, Gildengorin G, Feusner JH. Is routine computed tomographic scanning justified in the first week of persistent febrile neutropenia in children with malignancies?. Pediatr Blood Cancer 57(4):620-4, 2011. e-Pub 2011. PMID: 21265012.

Invited Articles

Greenbaum U, Mahadeo KM, Kebriaei P, Shpall EJ, Saini NY. Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Front Oncol 10:1594, 2020. e-Pub 2020. PMID: 32984022.

Review Articles

Saini N, Chopra B, Dhingra AK. Synergistic Effect of Piperine and its Derivatives: A Comprehensive Review. Curr Drug Res Rev 15(2):105-121, 2023. e-Pub 2023. PMID: 36321239.
Saini NY, Bathini V. Large granular lymphocytic leukemia-associated peripheral neuropathy. Ann Hematol 97(8):1501-1504, 2018. e-Pub 2018. PMID: 29568991.
Saini N, Mahindra A. Therapeutic strategies for the treatment of multiple myeloma. Discov Med 15(83):251-8, 2013. e-Pub 2013. PMID: 23636142.
Saini N, Mahindra A. Novel immunomodulatory compounds in multiple myeloma. Expert Opin Investig Drugs 22(2):207-15, 2013. e-Pub 2013. PMID: 23265189.
Saini N, Jacobson JO, Jha S, Saini V, Weinger R. The perils of not digging deep enough--uncovering a rare cause of acquired anemia. Am J Hematol 87(4):413-6, 2012. e-Pub 2012. PMID: 22120958.

Abstracts

Smallbone P, Saengboon S, Bashir Q, Nelson BE, Ramdial J, Saini NY, Hosing C, Popat UR, Delgado R, Becnel M, Lee HC, Orlowski R, Shpall EJ, Champlin RE, Qazilbash MH, Srour SA. Impact of Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) on AL Amyloidosis Outcomes. TANDEM Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
Nieto Y, Valdez BC, Thall P, Bassett R, Ramdial J, Srour SA, Saini NY, Hosing C, Alousi AA, Qazilbash MH, Popat UR, Barnett M, Gulbis AM, Shigle TL, Pacheco MV, Ledesma C, Ahmed S, Iyer SP, Nair R, Strati P, Westin JR, Champlin RE, Shpall EJ, Andersson BS. The Combination of the PARP Inhibitor Olaparib with High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT) Demonstrates High Activity for Refractory Lymphomas, Including Prior Failures of CAR-T. TANDEM Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
Kawedia JD, Liu X, Sui D, Gulbis AM, Ramdial J, Srour SA, Popat UR, Nieto Y, Kebriaei P, Saini NY, Lin P, Aljawai Y, Pasvolsky O, Lee HC, Orlowski RZ, Thomas SK, Patel KK, Knape C, Delgado R, Champlin RE, Shpall EJ, Qazilbash MH, Thall P, Bashir Q. Lower PG-Free Mel (Evomela) Clearance and Higher Exposure Are Associated with Better Treatment Response in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. TANDEM Meetings, Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2024. e-Pub 2024.
Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee HC, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood 65th Annual ASH Meeting 142((Suppl 1)):4972, 2023. e-Pub 2023.
Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience. Blood 65th Annual ASH Meeting 142((Suppl 1)):4963, 2023. e-Pub 2023.
Strati P, Brandt A, Henderson J, Westin J, Nastoupil LJ, Zaki AA, Jallouk AP, Adkins S, Shpall EJ, Kebriaei P, Ramdial J, Saini NY, Ahmed S, Flowers CR, Neelapu SS, Hildebrandt M. Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy. Blood 65th Annual ASH Meeting 142((Suppl 1)):5139, 2023. e-Pub 2023.
Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood 65th Annual ASH Meeting 142((Suppl 1)):4988, 2023. e-Pub 2023.
Jain MD, Yu X, Atkins R, Turner JG, Noble J, Menges M, Reid K, Corallo S, Cen L, Yoder SJ, Miranda JA, Naderinezhad S, Liu H, Shah BD, Chavez JC, Dean E, Fahrmann J, Saini NY, Hanash S, Hesterberg RS, Rodriguez PC, Cleveland JL, Davila M, Wang X, Locke FL. CAR-T Phenotype and Efficacy Is Impaired By Lymphoma-Associated CD39 + T Cells. Blood 65th Annual ASH Meeting 142((Suppl 1)):3500, 2023. e-Pub 2023.
Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation. Blood 65th Annual ASH Meeting 142((Suppl 1)):3356, 2023. e-Pub 2023.
Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation. Blood 65th Annual ASH Meeting 142((Suppl 1)):2215, 2023. e-Pub 2023.
Jhaveri K, Thapa R, Noble J, Ercan D, Singh P, Fahrmann J, Saini NY, Wu R, Dennison J, Hanash S, Jenq RR, Modi K, Figura N, Chavez JC, Shah BD, Nishihori T, Lazaryan A, Khimani F, Bachmeier CA, Gage K, Mishra A, Perna F, Davila M, Rejeski K, Subklewe M, Locke FL, L Freeman CL, Parker N, Jain MD. Impact of Sarcopenia and Subsequent Muscle Loss on Post-CAR T-Cell Outcomes in Relapsed/Refractory Large B-Cell Lymphoma. Blood 65th Annual ASH Meeting 142((Suppl 1)):2130, 2023. e-Pub 2023.
Weng J, Le CC, Pan Y, Perutelli F, Cheng X, Cao J, Agbedia O, Kuang S, Liu J, Chu F, Patchva S, Saini NY, Neelapu SS. Targeting B-Cell Malignancies with Anti-ROR1 CAR T-Cell Therapy. Blood 65th Annual ASH Meeting 142((Suppl 1)):6827, 2023. e-Pub 2023.
Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. Blood 65th Annual ASH Meeting 142((Suppl 1)):4962, 2023. e-Pub 2023.
Pasvolsky O, Patel KK, Bashir Q, Rauf M, Sui D, Srour SA, Tanner MR, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Weber DM, Becnel MR, Tang G, Orlowski RZ, Patel D, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. Blood 65th Annual ASH Meeting 142((Suppl 1)):7070, 2023. e-Pub 2023.
Rehman A, Rehman L, Devnani K, Le CC, Lin C, Cheng X, Chu F, Weng J, Liu J, Patchva S, Kuang S, Cao J, Richard M, Bruckheimer E, Neelapu SS, Saini NY. Effect of Ivospemin and Difluoromethylornithine Polyamine Inhibitors on Viability of Myeloma Cell Lines. Blood 65th Annual ASH Meeting 142((Suppl 1)):6589, 2023. e-Pub 2023.
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Shpall EJ, Champlin RE, Lin P, Qazilbash MH. Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Blood 64th ASH Annual Meeting 140(Supplement 1):284–286, 2022. e-Pub 2022.
Pasvolsky O, Milton DR, Masood A, Shehzad S, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowsky RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. Blood 64th ASH Annual Meeting 140(Supplement 1):10589–10591, 2022. e-Pub 2022.
Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramidal JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. Blood 64th ASH Annual Meeting 140(Supplement 1):4684–4685, 2022. e-Pub 2022.
Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Castillo LEM, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer WP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood 64th ASH Annual Meeting 140(Supplement 1):3800–3802, 2022. e-Pub 2022.
Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, An V, Samanieto F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. Blood 64th ASH Annual Meeting 140(Supplement 1):2313–2315, 2022. e-Pub 2022.
Nieto Y, Valdez BC, Thall PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood 64th ASH Annual Meeting 140(Supplement 1):1183–1184, 2022. e-Pub 2022.
Nieto Y, Banerjee PP, Kaur I, Griffin L, Ganesh C, Kerbauy L, Basar R, Kaplan M, Islam S, Esqueda D, Bassett R, Timmons M, Ramdial JL, Srour SA, Saini N, Hosing C, Ahmed S, Iyer SP, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood 64th ASH Annual Meeting 140(Supplement 1):415–416, 2022. e-Pub 2022.
Nieto Y, Banerjee P, Kaur I, Bassett R, Kerbauy L, Basar R, Kaplan M, Griffin L, Esqueda D, Ganesh C, Barnett M, Alousi A, Hosing C, Ramdial J, Saini N, Srour S, Alexis K, Harstrick A, Shpall EJ, Rezvani K. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. AACR Annual Meeting 2022, 2022. e-Pub 2022.
Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S461-S462, 2022. e-Pub 2022.
Srour SA, Saengboon S, Nelson BE, Ramdial J, Bashir Q, Vickers MR, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufamn G, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in AL Amyloidosis. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S426, 2022. e-Pub 2022.
Qazilbash MH, Bashir Q, Rauf M, Sui D, Srour SA, Popat UR, Saini NY, Hosing C, Ramdial J, Manasanch E, Lee HC, Kaufman G, Thomas S, Weber D, Becnel M, Tang G, Orlowski RZ, Guzman M, Champlin RE, Shpall EJ, Patel KK. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hemaptopoietic Stem Cell Transplantation. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S404-S405, 2022. e-Pub 2022.
Nelson BE, Ramdial J, Bashir Q, Saini NY, Hosing C, Popat UR, Delgado R, Lee HC, Kaufman G, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S414-S415, 2022. e-Pub 2022.
Gaballa M, Ma J, Tanner MR, Rauf M, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman G, Manasanch E, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S406-S407, 2022. e-Pub 2022.
Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, VAldez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S293, 2022. e-Pub 2022.
Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S83-S84, 2022. e-Pub 2022.
Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S82-S83, 2022. e-Pub 2022.
Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, ieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Transplant Cell Ther 2022 TCT Meetings of ASTCT and CIBMTR 28(3, Supplement):S78-S79, 2022. e-Pub 2022.
Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. J Clin Oncol 2022 ASCO Annual Meeting 40(Suppl 16):abstr 7536, 2022. e-Pub 2022.
Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma. J Clin Oncol 2022 ASCO Annual Meeting 40(Suppl 16):abstr e20024, 2022. e-Pub 2022.
Srour SA, Mehta RS, Shah N, Qazilbash MH, Im J, Bashir Q, Saini N, Nieto Y, Khouri IF, Daher M, Kebriaei P, Popat UR, Manasanch EE, Lee HC, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Rezvani K. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). J Clin Oncol 2022 ASCO Annual Meeting 40(Suppl 16):abstr 8009, 2022. e-Pub 2022.
Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):556, 2021. e-Pub 2021.
Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood 63rd ASH Annual Meeting 138(Supplement 1):3941, 2021. e-Pub 2021.
Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):2879, 2021. e-Pub 2021.
Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash M, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation:. Blood 63rd ASH Annual Meeting 138(Supplement 1):1803, 2021. e-Pub 2021.
Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood 63rd ASH Annual Meeting 138(Supplement 1):1802, 2021. e-Pub 2021.
Nelson BE, Ramdial JL, Bashir Q, Saini N, Hosing C, POpat UR, Delgado R, Lee HC, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH, Srour SA. Autologous Hematopoietic Stem Cell Transplantation for AL Amyloidosis Refractory to Induction Therapy. Blood 62nd ASH Annual Meeting 138(Supplement 1):482, 2021. e-Pub 2021.
Bashir Q, Milton DR, Rezvani K, Saini NY, Shpall EJ, Srour SA, Popat UR, Konopleva M, Pemmarju N, Champlin RE, Qazilbash MH. Phase 2 Study of Tagraxofusp Therapy for Patients with BPDCN Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 2021 TCT Meetings Digital Experience 27(3, Supplement):S432, 2021. e-Pub 2021.
Gaballa MR, Ma J, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas S, Webber D, Orlowski RZ, Sphall EJ, Champlin RE, Qazilbash MH. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 mg/m2 Conditioning, and Lenalidomide Maintenance. Transplant Cell Ther 2021 TCT Meetings Digital Experience 27(3, Supplement):S407-S408, 2021. e-Pub 2021.
Afrough A, Srour SA, Bashir Q, Saini NY, Hosing C, Popat UR, Kebriaei P, Delgado R, Murphy R, Manasanch E, Lee HC, Kaufman G, Patel KK, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction with VRD Vs. VCD on the Outcome of Patients with Multiple Myeloma after an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2021 TCT Meetings Digital Experience 27(3, Supplement):S405-S406, 2021. e-Pub 2021.
Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini NY, Srour SA, Hosing C, Manasanch E, Lee HC, Kaufman G, Patel KK, Orlowski RZ, Pinnix C, Dabaja B, Thomas S, Weber D, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 2021 TCT Meetings Digital Experience 27(3, Supplement):S411-S412, 2021. e-Pub 2021.
Iyer SP, Becnel MR, Nair R, Steiner R, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil N, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Jain P, Fayad L, Wang M, Miranda RN, Vega F, Flowers C, Neelapu SS. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):40-41, 2020. e-Pub 2020.
Ramdial JL, Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Weber DM, Kaufman GP, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):11-13, 2020. e-Pub 2020.
Afrough A, Alsfeld LC, Delgado R, Popat UR, Kebriaei P, Oran B, Saini N, Srour SA, Hosing C, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):22, 2020. e-Pub 2020.
Mukherjee A, Milton DR, Jabbour E, Daver N, Gulbis A, Ledesma G, Konopleva M, DiNardo CD, Ravandi F, Kadia TM, Alatrash G, Alousi AM, Daher M, Marin D, Olson AL, Oran B, Kebriaei P, Saini N, Srour SA, Popat UR, Im JS, Mehta R, Rondon G, Kantarjian HM, Champlin RE, Khouri IF. Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):13-14, 2020. e-Pub 2020.
Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):40-41, 2020. e-Pub 2020.
Saini N, Ma J, Timmons M, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash M, Shpall EJ, Srour SA, Valdez BC, Dabaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):32-33, 2020. e-Pub 2020.
Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Kebriaei P, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):10-12, 2020. e-Pub 2020.
Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):24-25, 2020. e-Pub 2020.
Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):23-24, 2020. e-Pub 2020.
Afrough A, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Prognostic Impact of Beta 2 Microglobulin in Patients with Immunoglobulin Light-Chain Amyloidosis Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):20-21, 2020. e-Pub 2020.
Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial J, Neito Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):14-15, 2020. e-Pub 2020.
Saini N, Chang CC, Strati P, Nastoupil LJ, Westin J, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner RE, Greenbaum U, Kebriaei P, Shpall EJ, Jain N, Green MR, Ajami NJ, Flowers C, Champlin RE, Wargo J, Neelapu SS, Jenq RR. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):34-35, 2020. e-Pub 2020.
Afrough A, Alsfeld LC, Srour SA, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Shpall EJ, Delgado R, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with t(11;14) Undergoing Autologous Hematopoietic Stem Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):18-19, 2020. e-Pub 2020.
Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, Mahadeo M, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):17-18, 2020. e-Pub 2020.
Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):9-10, 2020. e-Pub 2020.
Ramdial J, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):6-7, 2020. e-Pub 2020.
Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):46-47, 2020. e-Pub 2020.
Bashir Q, Rezvani K, Saini N, Shpall EJ, Srour SA, Popat UR, Milton DR, Pemmaraju N, Champlin RE, Qazilbash MH. Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. Blood 62nd ASH Annual Meeting and Exposition 136(Supplement 1):5, 2020. e-Pub 2020.
Joseph J, Milton D, Chen J, Al-Atrash G, Alousi A, Bashir Q, Ciurea S, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Andersson B, Champlin R, Popat U. Myeloablative fludarabine and busulfan regimen in myelofibrosis: long term outcomes and analysis of prognostic factors. HemaSphere EHA25 Virtual 4(S1):507, 2020. e-Pub 2020.
Srour SA, Milton DR, Bashir Q, Mehta RS, Saini N, Ciurea SO, Daher M, Popat U, Khouri I, Kebriaei P, Delgado R, Rondon G, Manasanch EE, Patel K, Lee HC, Shpall E, Orlowski R, Champlin R, Qazilbash MH. Survival trends in multiple myeloma after autologous hematopietic stem cell transplantation. HemaSphere EHA25 Virtual 4(S1):487, 2020. e-Pub 2020.
Popat U, Mehta RS, Bassett Jr R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Daher M, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem J, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan conditioning regimen in older patients: results of a phase II study. HemaSphere EHA25 Virtual 4(S1):637, 2020. e-Pub 2020.
Yalniz F, Milton D, Greenbaum U, Popat U, Nieto Y, Srour S, Saini N, Kebriaei P, Oran B, Al-Atrash G, Delgado R, Champlin R, Qazilbash M, Bashir Q. Characteristics and outcomes of patients with multiple myeloma who developed therapy related myeloid. HemaSphere EHA25 Virtual 4(S1):366, 2020. e-Pub 2020.
Joseph J, Milton D, Chen J, Al-Atrash G, Alousi A, Bashir Q, Ciurea S, Daher M, Im J, Mehta R, Olson A, Oran B, Saini N, Srour S, Andersson B, Champlin R, Popat U. Myeloablative fludarabine and busulfan regimen in myelofibrosis: Long term outcomes and analysis of prognostic factors. J Clin Oncol 2020 ASCO Virtual Scientific Program 38(15_suppl):e19520, 2020. e-Pub 2020.
Srour SA, Milton DR, Bashir Q, Mehta RS, Saini N, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Delgao R, Rondon G, Manasanch E, Patel K, Lee HC, Shpall EJ, Rz O, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 2020 TCT Meetings of ASBMT & CIBMTR 26(3, Supplement):S238-S239, 2020. e-Pub 2020.
Popat UR, Saliba RM, Mehta RS, Olson A, Chen J, Ganesh C, Woodworth G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour SA, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Comparison of Post-Transplant Cyclophosphamide and Tacrolimus and Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Biol Blood Marrow Transplant 2020 TCT Meetings of ASBMT & CIBMTR 26(3, Supplement):S125, 2020. e-Pub 2020.
Popat U, Mehta RS, Bassett R, Olson A, Chen J, Ganesh C, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Sa S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Biol Blood Marrow Transplant 2020 TCT Meetings of ASBMT & CIBMTR 26(3, Supplement):S6-S7, 2020. e-Pub 2020.
Ramdial J, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing CM, Popat UR, Lee, HC, Patel K, Yalniz FF, Champlin RE, Qazilbash MH. Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Growth Factors Only Vs. Growth Factors + Chemotherapy. Biol Blood Marrow Transplant 2020 TCT Meetings of ASBMT & CIBMTR 26(3, Supplement):S286-S287, 2020. e-Pub 2020.
Popat U, Saliba RM, Mehta RS, Olson AL, Chen J, Ganesh C, Rondon G, Woodword G, McMullin B, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash MH, Molldrem JJ, Shpall EJ, Andersson BS, Champlin RE. Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receiving Myeloablative Fractionated Busulfan Conditioning Regimen. Blood 61st ASH Annual Meeting 134(Supplement_1):3296, 2019. e-Pub 2019.
Popat U, Mehta RS, Bassett R, Olson AL, Chen J, Ganesh C, Alousi AM, Anderlini A, Alatrash G, Bashir B, Ciurea SO, Hosing C, Im JS, Kebriaei P, If K, Marin D, Nieto Y, Oran B, Saini N, Srour S, Rezvani K, Qazilbash M, Molldrem JJ, Shpall EJ, Andersson BS, Champlin ES. Myeloablative Fractionated Busulfan Conditioning Regimen in Older Patients: Results of a Phase II Study. Blood 61st ASH Annual Meeting 134(Supplement_1):256, 2019. e-Pub 2019.
Saini N, Patel R, Srour S, Bashir Q, Saeed A, Rafique AJ, Qazilbash Q. Impact of cytogenetics versus FISH detected t(11;14) in newly diagnosed multiple myeloma patients with upfront transplantation. Clin Lymphoma Myeloma Leuk 17th International Myeloma Workshop 19(10, Supplement):e218-e219, 2019. e-Pub 2019.
Varma A, Abraham SC, Saini N, Bashir Q, Rondon G, Srour SA, Mehta RS, Olson A, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Shpall EJJ, Champlin RE, Popat UR. Idiopathic portal hypertension related refractory ascites (IPHRA) after allogeneic stem cell transplant. Biol Blood Marrow Transplant 2019 TCT Meetings of ASTCT and CIBMTR 25(3, Supplemental):S144-S145, 2019. e-Pub 2019.
Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini N, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, Fenske TS. Post-relapse survival in diffuse large b-cell lymphoma (DLBCL) patients after experiencing therapy failure following autologous hematopoietic cell transplantation (auto-HCT). Biol Blood Marrow Transplant 2019 TCT Meetings of ASTCT and CIBMTR 25(3, Supplemental):S22, 2019. e-Pub 2019.
Saini N, Saliba RM, Patel RD, Abdulrazzaq MN, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Kebriaei P, Nastoupil L, Westin JR, Rondon G, Andersson BS, Champlin RE, Muzzafar TR, Nieto Y, Ahmed S. Does cell of origin classification impact outcomes in diffuse large b-cell lymphoma after autologous stem cell transplant. Biol Blood Marrow Transplant 2019 TCT Meetings of ASTCT and CIBMTR 25(3, Supplemental):S394-S395, 2019. e-Pub 2019.
Saini N, Cerny J, Furtado V, Puthawala I, Desmond A, Ramanathan M, Nath R. Hematopoeitic cell transplant - Comorbidity index (HCT-CI) score is a useful tool for predicting induction mortality and overall survival in newly diagnosed acute myeloid leukemia patients. Blood 60th ASH Annual Meeting 132(Supplement 1):1396, 2018. e-Pub 2018.
Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of multiple myeloma with chromosome 1q Gain and 1p Deletion after high-dose therapy and autologous hematopoietic stem cell transplantation. Blood 60th ASH Annual Meeting 132(Supplement 1):4609, 2018. e-Pub 2018.
Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Ch H, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khyouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic transplantation for lymphoid malignancies with fludarabine and melphalan conditioning and different donor types. Blood 60th ASH Annual Meeting 132(Supplement 1):3356, 2018. e-Pub 2018.
Saini N, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM. Impact of t(11;14) on the outcome of autologous tranplantation in multiple myeloma: a matched pair analysis. Blood 60th ASH Annual Meeting 132(Supplement 1):4607, 2018. e-Pub 2018.
Saini N, Patel R, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable responses after autologous stem cell transplantation in POEMS Syndrome. Blood 60th ASH Annual Meeting 132(Supplement 1):4606, 2018. e-Pub 2018.
Saini N, Patel R, Varma A, Bashir Q, Delgado R, Popat U, Hosing C, Nieto Y, Kebriaei P, Alouis AM, Ahmed S, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplantation in the octogenarian multiple myeloma patient population. Blood 60th ASH Annual Meeting 132(Supplement 1):4608, 2018. e-Pub 2018.
Saini N, Cerny J, Furtado V, Desmond A, Zheng Z, Raffel GD, Puthawala I, Bednarik J, Shanahan L, Miron PM, Woda B, Ramanathan M, Nath R. High dose mitoxantrone based "5+1" induction chemotherapy regimen in newly diagnosed acute myeloid leukemia. Blood 60th ASH Annual Meeting 132(Supplement 1):1430, 2018. e-Pub 2018.
Margapuri J, Saini N, Bathini V. Bing-Neel Syndrome - A rare presentation of lymphoplasmacytic lymphoma. Anticancer Res 5th ICAAHO 38(3):1833-1834, 2018. e-Pub 2018.
Patel R, Saini N, Varma A, Hasan O, Bashir Q, Delgado R, Popat U, Hosing C, Mukherjee A, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of autologous stem cell transplantation in Waldenstrom's Macroglobulinemia. Blood 60th ASH Annual Meeting 132(Supplement 1):2149, 2018. e-Pub 2018.
Suzuki S, Racine RR, Manalo NA, Saini N, Odour C, Moazami M, Bailey JA, Watts JK, Raffel GD. Targeting the mechanism of C-Mpl exon-inclusion through antisense oligonucleotides yields a dominant negative isoform. Blood 59th ASH Annual Meeting 130(Supplement 1):383, 2017. e-Pub 2017.
Saini N, Zhou Z, Yarta K, Mathew C, Ramanathan M, Nath R, Cerny J. Cardiac risk factors and echocardiographic variables as Predictors of mortality in bone marrow transplant patients. Biol Blood Marrow Transplant 2016 BMT Tandem Meetings 22(3, Supplement):S307-S308, 2016. e-Pub 2016.
Tuazon S, Daskalakis C, Saini N, Mandala A, O'Hara WJ, Sharma M, Flicko-O'Hara J, Carabasi M, Grosso D, Alpdogan O, Martinez-Outschoorn U, Kasner M, Flomenberg N, Weiss M, Wagner J. Comparison of engraftment syndrome with G-CSF versus GM-CSF after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S145-S146, 2015. e-Pub 2015.
Sharma M, Gooptu M, Klumpp T, Saini N, Mandala A, Tuazon S, Nagalla S, Wagner J, Kasner M, Alpdogan O, Martinez U, Grosso D, Filcko J, Pro B, Carabasi M, Flomenberg N, Weiss M. Management of catheter-related thrombosis in patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant 2015 BMT Tandem Meetings 21(2, Supplement):S250-S251, 2015. e-Pub 2015.
Webb J, Le N, Hall NE, Saini N, Herman JH. Challenges and outcomes in applying pediatric stroke prophylaxis guidelines to adult sickle cell patients. Transfusion AABB Annual Meeting 54(S2):15A-268A, 2014. e-Pub 2014.
Kansagra AJ, Brooks, G, Gao JH, Jamili L, Kundi M, Saini N, Stankiewicz R, Rao SR, Linden EA, Jacobson JO. Risk factors for the development of chemotherapy-related hospitalization (CRH) in patients treated with palliative intent: Results of a 9-year nested case control study. J Clin Oncol 2013 ASCO Quality Care Symposium 31(15_suppl):3, 2013. e-Pub 2013.
Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. TANDEM Meetings of ASTCT and CIBMTR 2025.
Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Siddiqui UR, Khan HN, Haider AA, Ramdial JL, Nieto Y, Tang G, Lakhani K, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE. Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance. TANDEM Meetings of ASTCT and CIBMTR 2025.
Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. TANDEM Meetings of ASTCT and CIBMTR 2025.
Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Srour SA. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. TANDEM Meetings of ASTCT and CIBMTR 2025.
Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Saeed A, Haider AA, Ramdial JL, Nieto Y, Tang G, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Becnel MR, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. TANDEM Meetings of ASTCT and CIBMTR 2025.
Deen AF, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Predictive Factors for Transplant Outcomes of Cardiac AL Amyloidosis. TANDEM Meetings of ASTCT and CIBMTR 2025.
Sami SS, Bashir Q, Saini NY, Aljawai YM, Hosing CM, Popat UR, Becnel MR, Kaufman GP, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Age on Autologous Stem Cell Transplantation Outcomes for AL Amyloidosis. TANDEM Meetings of ASTCT and CIBMTR 2025.
Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. TANDEM Meetings of ASTCT and CIBMTR 2025.

Book Chapters

Saini N. Autologous Stem Cell Transplantation in Multiple Myeloma. In: MD Anderson Cancer Center Manual of Oncology, 2023.

Letters to the Editor

Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204: e11-e16, 2024.
Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201: e37-e41, 2023.
Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety of CAR T-cell therapy in kidney transplant recipients. Blood 137: 2558-2562, 2021.
Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193: e23-e26, 2021.
Ciurea SO, Kongtim P, Srour S, Saini N, Im J, Ramdial J, Khouri I, Anderlini P, Popat U, Hosing C, Champlin RE, Lee HJ, Fayad LE, Hagemeister FB, Bica AM, Lipan L, Craciun O, Jercan CG, Tanase A, Colita A. Can we cure refractory Hodgkin's lymphoma with transplantation?. Bone Marrow Transplant 56: 278-281, 2021.
Saini N, Saini V, Kumar V, Bhatia A, Qazi S. 18F-FDG positron emission tomography scan findings in a case of rituximab-CHOP-induced pneumonitis. Indian J Cancer 52: 437-438, 2015.

Less

CV information above last modified July 22, 2026

Neeraj Saini, MD

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Extramural Institutional Committee Activities

Professional Memberships

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Neeraj Saini, MD

Present Title & Affiliation

Primary Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Extramural Institutional Committee Activities

Professional Memberships

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson